hello world
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.
Stocks in play: Entheon Biomedical Corp.
Announced that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc., is now available for sale in Canada and the United States. Entheon, a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, via its Subsidiary HaluGen Life Sciences, has expanded its genetic test panel to include the CYP2D6 gene, a marker indicating the metabolism of LSD, MDMA and ayahuasca. Entheon Biomedical Corp shares C.ENBI are trading down $0.03 at $0.39.
